Abstract


 Injectable diacetylmorphine might provide more benefits and lower costs compared with oral methadone maintenance therapy in patients with severe opioid use disorder.
 The Canadian Research Initiative in Substance Misuse guideline recommends that both injectable diacetylmorphine and hydromorphone should be considered as treatment options for individuals with severe, treatment-refractory opioid use disorder and ongoing illicit injection opioid use, and that the injectable opioid agonist treatment should have an end date to transition to an oral opioid agonist treatment.
 No recent studies on the clinical effectiveness of diacetylmorphine for injection in comparison with methadone or buprenorphine were identified.
 No cost-effectiveness studies of injectable diacetylmorphine compared with buprenorphine were identified.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call